{"denoms":[{"counts":[{"groupId":"BG000","value":"329"},{"groupId":"BG001","value":"332"},{"groupId":"BG002","value":"661"}],"units":"Participants"}],"groups":[{"description":"Vorinostat three 100 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment continued until disease progression or unacceptable toxicity.","id":"BG000","title":"Vorinostat"},{"description":"Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment continued until disease progression or unacceptable toxicity.","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.5","value":"64.2"},{"groupId":"BG001","spread":"9.3","value":"64.4"},{"groupId":"BG002","spread":"9.4","value":"64.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"108"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"283"},{"groupId":"BG001","value":"270"},{"groupId":"BG002","value":"553"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}